|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
73,500,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nuvalent is a biopharmaceutical company. Co.'s product candidate, NVL-520, is a ROS proto-oncogene 1 (ROS1)-selective inhibitor designed with the aim to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of available ROS1 tyrosine kinase inhibitors. Co.'s another product candidate, NVL-655, is a brain-penetrant anaplastic lymphoma kinase (ALK)-selective inhibitor, designed with the aim to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that may limit the use of first-, second-, and third-generation ALK inhibitors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
89,200 |
246,996 |
3,760,625 |
5,464,329 |
| Total Sell Value |
$6,417,253 |
$18,467,081 |
$347,611,898 |
$467,050,229 |
| Total People Sold |
3 |
7 |
10 |
11 |
| Total Sell Transactions |
6 |
20 |
52 |
101 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pelish Henry E. |
Chief Scientific Officer |
• – – |
2025-06-27 |
4 |
AS |
$79.92 |
$173,426 |
D/D |
(2,170) |
63,101 |
|
- |
|
| Pelish Henry E. |
Chief Scientific Officer |
• – – |
2025-06-27 |
4 |
OE |
$27.85 |
$63,133 |
D/D |
2,170 |
65,271 |
|
- |
|
| Noci Darlene |
Chief Development Officer |
• – – |
2025-06-26 |
4 |
AS |
$77.38 |
$314,826 |
D/D |
(4,000) |
48,034 |
|
- |
|
| Noci Darlene |
Chief Development Officer |
• – – |
2025-06-26 |
4 |
OE |
$27.85 |
$111,400 |
D/D |
4,000 |
52,034 |
|
- |
|
| Pelish Henry E. |
Chief Scientific Officer |
• – – |
2025-06-25 |
4 |
AS |
$79.87 |
$689,278 |
D/D |
(8,630) |
63,101 |
|
- |
|
| Pelish Henry E. |
Chief Scientific Officer |
• – – |
2025-06-25 |
4 |
OE |
$27.85 |
$247,676 |
D/D |
8,630 |
71,731 |
|
- |
|
| Srivastava Sapna |
|
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,647 |
5,146 |
|
- |
|
| Meyers Michael L. |
|
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,647 |
5,146 |
|
- |
|
| Pearlberg Joseph |
|
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,647 |
5,146 |
|
- |
|
| Shair Matthew |
|
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,647 |
1,429,844 |
|
- |
|
| Bogle Grant C. |
|
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,647 |
5,847 |
|
- |
|
| Protopapas Anna |
|
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,647 |
5,146 |
|
- |
|
| Wheeler Cameron |
|
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,647 |
5,146 |
|
- |
|
| Oliger Christy J. |
|
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
3,971 |
3,971 |
|
- |
|
| Deerfield Management Co /ny |
Director by Deputization |
– • • |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
I/I |
5,294 |
2,647 |
|
- |
|
| Porter James Richard |
President and CEO |
• • – |
2025-06-16 |
4 |
AS |
$76.66 |
$2,077,093 |
D/D |
(27,000) |
249,062 |
|
- |
|
| Porter James Richard |
President and CEO |
• • – |
2025-06-16 |
4 |
OE |
$27.85 |
$751,950 |
D/D |
27,000 |
276,062 |
|
- |
|
| Pelish Henry E. |
Chief Scientific Officer |
• – – |
2025-06-06 |
4 |
AS |
$79.82 |
$15,964 |
D/D |
(200) |
63,101 |
|
- |
|
| Pelish Henry E. |
Chief Scientific Officer |
• – – |
2025-06-06 |
4 |
OE |
$27.85 |
$5,718 |
D/D |
200 |
63,301 |
|
- |
|
| Noci Darlene |
Chief Development Officer |
• – – |
2025-05-29 |
4 |
AS |
$71.25 |
$285,236 |
D/D |
(4,000) |
48,034 |
|
- |
|
| Noci Darlene |
Chief Development Officer |
• – – |
2025-05-29 |
4 |
OE |
$14.40 |
$82,765 |
D/D |
4,000 |
52,034 |
|
- |
|
| Porter James Richard |
President and CEO |
• • – |
2025-05-15 |
4 |
AS |
$69.28 |
$1,879,216 |
D/D |
(27,000) |
249,062 |
|
- |
|
| Porter James Richard |
President and CEO |
• • – |
2025-05-15 |
4 |
OE |
$27.85 |
$751,950 |
D/D |
27,000 |
276,062 |
|
- |
|
| Noci Darlene |
Chief Development Officer |
• – – |
2025-04-29 |
4 |
AS |
$74.56 |
$298,240 |
D/D |
(4,000) |
48,034 |
|
- |
|
| Noci Darlene |
Chief Development Officer |
• – – |
2025-04-29 |
4 |
OE |
$14.40 |
$57,600 |
D/D |
4,000 |
52,034 |
|
- |
|
288 Records found
|
|
Page 1 of 12 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
